- Home
- EDTK vs VYNE Comparison
EDTK vs VYNE Comparison
Compare EDTK & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDTK
- VYNE
- Stock Information
- Founded
- EDTK 2013
- VYNE 2003
- Country
- EDTK China
- VYNE United States
- Employees
- EDTK N/A
- VYNE N/A
- Industry
- EDTK Other Consumer Services
- VYNE Biotechnology: Pharmaceutical Preparations
- Sector
- EDTK Real Estate
- VYNE Health Care
- Exchange
- EDTK Nasdaq
- VYNE Nasdaq
- Market Cap
- EDTK 14.7M
- VYNE 16.0M
- IPO Year
- EDTK 2020
- VYNE 2018
- Fundamental
- Price
- EDTK $0.88
- VYNE $1.42
- Analyst Decision
- EDTK
- VYNE Strong Buy
- Analyst Count
- EDTK 0
- VYNE 2
- Target Price
- EDTK N/A
- VYNE $6.25
- AVG Volume (30 Days)
- EDTK 6.5K
- VYNE 964.9K
- Earning Date
- EDTK 08-18-2025
- VYNE 08-13-2025
- Dividend Yield
- EDTK N/A
- VYNE N/A
- EPS Growth
- EDTK N/A
- VYNE N/A
- EPS
- EDTK N/A
- VYNE N/A
- Revenue
- EDTK $624,365.00
- VYNE $605,000.00
- Revenue This Year
- EDTK N/A
- VYNE $42.51
- Revenue Next Year
- EDTK N/A
- VYNE N/A
- P/E Ratio
- EDTK N/A
- VYNE N/A
- Revenue Growth
- EDTK N/A
- VYNE 43.03
- 52 Week Low
- EDTK $0.80
- VYNE $0.85
- 52 Week High
- EDTK $1.27
- VYNE $4.30
- Technical
- Relative Strength Index (RSI)
- EDTK 43.35
- VYNE 77.62
- Support Level
- EDTK $0.85
- VYNE $0.85
- Resistance Level
- EDTK $0.95
- VYNE $0.97
- Average True Range (ATR)
- EDTK 0.06
- VYNE 0.13
- MACD
- EDTK -0.00
- VYNE 0.08
- Stochastic Oscillator
- EDTK 22.28
- VYNE 85.56
About EDTK Skillful Craftsman Education Technology Limited
Skillful Craftsman Education Technology Ltd provides online education and technology services in China. The services comprises of two aspects - Online vocational training and Virtual simulation experimental training. It covers a wide range of subjects, including mechanics, electronics, auto repair and construction. Majority of its revenues are generated from the People's Republic of China.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.